secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARVARD BIOSCIENCE INC (HBIO)
CIK:        0001123494
Form:       8-K
Filed at:   2025-07-17T23:59:59+00:00
Accession:  0001171843-25-004508
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harvard Bioscience appoints John Duke as CEO; Q2 revenue anticipated at $20.4M
------------------------------------------------------------------------------

- Jim Green resigns as President & CEO effective July 28, 2025; retirement not due to any disagreement.
- John Duke (current board member) appointed CEO effective July 28; base salary $480K, 500k RSU grant.
- Rob Gagnon and Seth Benson appointed to Board; Gagnon to chair Audit and Compensation committees.
- Preliminary Q2 2025 revenue of $20.4 million; gross margin guidance reiterated at 55%-57%.
- Full Q2 2025 financial results expected to be reported on August 11, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1123494/000117184325004508/0001171843-25-004508-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1123494/000117184325004508/f8k_071725.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-004508

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer